Summary: The collapse of SVB Financial Group shook stocks yet again, leaving investors wondering what
Summary: AbbVie’s Q4 2022 earnings beat market expectations, but ABBV’s full-year 2022 bottom line came
Summary: We share another of the 22 Mega Cap stocks with the prospect of higher
Summary: There is widespread concern about the impact of Humira biosimilars being available in the
Summary: AbbVie has seen its shares pull back in recent weeks. Humira has gone off
Summary: The day has arrived: Biosimilars for the blockbuster drug Humira are now being sold
Summary: According to the financial report of Johnson & Johnson, a partner of AbbVie, sales
Summary: AbbVie is one of the largest global Pharmaceuticals, with a market cap of >$265bn.
Summary: AbbVie is a quality BBB+ S&P credit rated healthcare stock with a 3.9% yield.
Summary: 2023 is likely to start out weak for stocks, and they could potentially fall